Abstract: The invention relates to a compound of formula I, and a preparation method and use thereof. The compound has a bacterial quorum-sensing regulatory effect, and can be used for prevention and/or treatment of a disease caused by a bacterial infection.

Abstract: A derivative of homoserine lactone represented by formula I, and a preparation method and use thereof. The compound has a bacterial quorum-sensing regulatory effect, and can be used for prevention and/or treatment of a disease caused by a bacterial infection.

Abstract: The present invention relates to a compound of Formula I, or an isomer, pharmaceutically acceptable salt and solvate of the compound, and to a composition comprising the compound of Formula I, or the isomer, pharmaceutically acceptable salt and solvate thereof, and a pharmaceutically acceptable carrier, excipient or diluents. The present invention also relates to use of the compound of Formula I, or the isomer, pharmaceutically acceptable salt and solvate thereof for combating apoptosis, preventing or treating a disease or disorder associated with apoptosis; and especially use for protecting cardiomyocyte, and for preventing or treating a disease or disorder associated with cardiomyocyte apoptosis.

Abstract: In general, techniques are described for ensuring the distribution of Virtual Private Network (VPN) routes in a service provider network configured with multiple VPN services. In some examples, a network device receives configuration data that defines a VPN service associated with a route target. The network device, responsive to receiving the configuration data, sends a request for routes that match a type of the VPN service to a routing protocol speaker. The network device receives routes that match the type of the VPN service and are associated with the route target, installs the routes that match the type of the VPN service and are associated with the route target to the routing information base. The network device forwards traffic for the VPN service in accordance with the installed routes.

Abstract: The present invention relates to a thiazine amide derivative and a pharmaceutical use thereof, and particularly to a compound of formula I (in the formula, variables are as described in the specification), a pharmaceutically acceptable salt, solvate or hydrate thereof. The present invention further relates to a method for preparing the compound, a pharmaceutical composition containing the compound, and a method or use thereof for prevention or treatment of neurodegenerative diseases.

Abstract: Disclosed is a portal push method, which comprises: a broadband remote access server (BRAS) equipment acquiring a website identification list, after the BRAS equipment receives a hypertext transport protocol (HTTP) request message sent by a user terminal. The BRAS equipment determines whether to send portal pages to the user terminal according to whether the identification of a target website visited by the user client has a matched item in the list. The embodiments of the present disclosure further provide a corresponding BRAS equipment. The technical solutions of the embodiments of the present disclosure can reduce push times of invalid portals and improve portal push success rate.

Abstract: A network device identifies an Open Shortest Path First (OSPF) link between the network device and a layer 2 network as one of a point-to-multipoint over broadcast interface or a point-to-multipoint over non-broadcast multi access (NBMA) interface, and performs database synchronization and neighbor discovery and maintenance using one of a broadcast model or a NBMA model. The network device also generates a link-state advertisement for the network device, where the link-state advertisement includes a separate link description for each point-to-point link within the layer 2 network; and sends the link-state advertisement to each fully adjacent neighbor in the layer 2 network.

Abstract: The present invention relates to (1S,2S,3S,4R)-3-[(1S)-1-acetylamino-2-ethyl-butyl]-4-guanidino-2-hydroxy-cyclopentyl-1-carboxylic acid hydrates compounds, preparing methods thereof, pharmaceutical compositions containing said compounds and preparing methods thereof, and the clinical uses of said compounds as neuramidinase inhibitors for anti-influenza.

Abstract: Provided are piperazinyl pyrimidine derivatives of formula I having CCR4 antagonism, and the preparation method, pharmaceutical composition and use thereof in the preparation of a medicament. The medicament is useful for the treatment and prevention of CCR4-related diseases.

Abstract: A method, a device, and a network system of establishing a tunnel are provided in embodiments of the present disclosure. The method of establishing the tunnel includes: obtaining, by a WTP, an address of an AC and an address of a BRAS from a DHCP server; using, by the WTP, the address of the AC to establish a CAPWAP control tunnel with the AC; and using, by the WTP, the address of the BRAS to establish a CAPWAP data tunnel with the BRAS. By using the technical scheme provided in the embodiments of the present disclosure, the CAPWAP data tunnel may be established between the WTP and the BRAS.

Abstract: Techniques are described for utilizing two-part metrics with link state routing protocols of computer networks. For example, link state advertisements communicated by a router convey outbound cost metrics representative of outbound costs for the router to send network traffic to a network, and inbound cost metrics representative of inbound costs to receive network traffic from the network. The techniques may be particularly useful with respect to shared access networks, including broadcast or non-broadcast multi-access networks.

Abstract: A load sharing method, system, and access server has been disclosed. The load sharing method includes: sending request information to at least two authentication authorization accounting servers, receiving respective state information sent by the at least two authentication authorization accounting servers according to the request information, determining a load sharing ratio among the at least two authentication authorization accounting servers according to the respective state information, and sharing loads among the at least two authentication authorization accounting servers according to the load sharing ratio. The access server can adjust the load sharing ratio among the authentication authorization accounting servers dynamically, which improves user access performance.

Abstract: A network device identifies an Open Shortest Path First (OSPF) link between the network device and a layer 2 network as one of a point-to-multipoint over broadcast interface or a point-to-multipoint over non-broadcast multi access (NBMA) interface, and performs database synchronization and neighbor discovery and maintenance using one of a broadcast model or a NBMA model. The network device also generates a link-state advertisement for the network device, where the link-state advertisement includes a separate link description for each point-to-point link within the layer 2 network; and sends the link-state advertisement to each fully adjacent neighbor in the layer 2 network.

Abstract: A network device receives a join request on a downstream interface, wherein the join request specifies a source device and multicast group, wherein the network device is positioned within a core network of a multicast virtual private network (MVPN) that transmits multicast traffic between the source device and a plurality of receivers associated with customer sites. The network device selects an upstream router to which to send the join request from among a plurality of upstream routers on paths leading to the source device, so as to avoid creating a join request loop in the core network. At least one of the upstream routers is positioned on an Exterior Border Gateway Protocol (EBGP) path toward the source device, and at least one of the upstream routers is positioned on an Interior BGP (IBGP) path toward the source device. The network device sends the join request to the selected upstream device.

Abstract: Disclosed are pyridazine derivatives represented by Formula I or pharmaceutically acceptable salts or hydrates thereof, pharmaceutical compositions comprising the compounds, methods of treating and/or preventing diseases or disorders associated with viral infections in patients using the compounds, and the use of the compounds in preparing the medicaments for treating and/or preventing diseases or disorders associated with viral infections. The compounds represented by Formula I have antiviral activity, especially anti-microRNA viral activity. Symbols in the compounds represented are described in the specification.

Abstract: A method, a device, and a network system of establishing a tunnel are provided in embodiments of the present disclosure. The method of establishing the tunnel includes: obtaining, by a WTP, an address of an AC and an address of a BRAS from a DHCP server; using, by the WTP, the address of the AC to establish a CAPWAP control tunnel with the AC; and using, by the WTP, the address of the BRAS to establish a CAPWAP data tunnel with the BRAS. By using the technical scheme provided in the embodiments of the present disclosure, the CAPWAP data tunnel may be established between the WTP and the BRAS.

Abstract: The present invention relates to a compound of Formula I, or an isomer, pharmaceutically acceptable salt and solvate thereof; to a composition comprising a compound of Formula I, or an isomer, pharmaceutically acceptable salt and solvate thereof, and a pharmaceutically acceptable carrier, excipient or diluent; and also to use of a compound of Formula I, or an isomer, pharmaceutically acceptable salt and solvate thereof for combating apoptosis, or preventing or treating a disease or disorder associated with apoptosis; and especially use for protecting cardiomyocyte, or preventing or treating a disease or disorder associated with cardiomyocyte apoptosis.

Abstract: The present invention relates to an acrylamide compound of Formula I, or an isomer, pharmaceutically acceptable salt and solvate thereof, to a composition comprising the compound or an isomer, pharmaceutically acceptable salt and solvate thereof, and a pharmaceutically acceptable carrier, excipient or diluent, and to a use of the compound or the composition for prophylaxis and/or treatment of a disease or disorder associated with cardiomyocyte apoptosis.

Abstract: Disclosed are pyridazine derivatives represented by Formula I or pharmaceutically acceptable salts or hydrates thereof, pharmaceutical compositions comprising the compounds, methods of treating and/or preventing diseases or disorders associated with viral infections in patients using the compounds, and the use of the compounds in preparing the medicaments for treating and/or preventing diseases or disorders associated with viral infections. The compounds represented by Formula I have antiviral activity, especially anti-microRNA viral activity. Symbols in the compounds represented are described in the specification.

Abstract: A method of identifying compounds as direct inhibitors of Keap1-Nrf2 interaction through high-throughput screening and lead development. The direct inhibitors of Keap1-Nrf2 interaction are more specific and free of various undesirable effects than existing indirect inhibitors, and are potential drug candidates of chemopreventive and therapeutic agents for treatment of various diseases or conditions involving oxidative stress and/or inflammation, including but not limited to cancers, diabetes, Alzheimer's, and Parkinson's. Novel compounds are identified and methods of preventing or treating diseases or conditions related to Keap1-Nrf2 interaction activity by use of the novel compounds identified or compositions containing such compounds are also disclosed.